SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Marker Therapeutics receives $16.2 million CPRIT grant for MT-601 trial

The grant will support development of MT-601 in the Phase 2 APOLLO study.

MRKR

Related stories